EMPEROR-Reduced

March 15, 2019

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

  • Clinical Trial Information

    Trial Contact: Noel, Henry

    Trial Phone: 321.841.3686

  • IRB No: 18.025.02

    Protocol Abbrev: EMPEROR-Reduced

    Principal Investigator: Bhupinder R. Gupta, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: 2016-002280-34 EudraCT Number

    Treatment: Drug: Empagliflozin

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT03057977

  • Objective

    Demonstrate superiority of empagliflozin 10 mg versus placebo on top of guideline-directed medical therapy in patients with symptomatic, chronic HF and reduced ejection fraction (LVEF ≤
    40%).

  • Key Eligibility

    1. Heart Failure Class II-IV
    2. Reduced Ejection Fraction
    3. Appropriate Medical Therapy